Introduction {#section1-1534735418810799}
============

Cancer is a major public health problem and has emerged as a leading cause of death globally. Although significant progress has been made in research into the cause of cancer, effective strategies to inhibit the carcinogenic process still lag behind.^[@bibr1-1534735418810799]^ By 2020, the world population is expected to have increased to 7.5 billion; of this number, approximately 15 million new cancer cases will be diagnosed.^[@bibr2-1534735418810799]^ After being diagnosed, chemotherapy is the most frequently used way to control disease and to extend survival.^[@bibr3-1534735418810799]^ However, chemotherapy-induced toxicities critically cause various complications, increasing the risk of chemotherapeutic failure.^[@bibr4-1534735418810799]^ Based on these problems, clinical workers are actively looking for complementary and alternative therapies for enhancing effectiveness and relieving symptoms of chemotherapy. In China, there has been a long history of using traditional Chinese herbal medicine (TCM) as one kind of adjuvant medicine, combined with antitumor drugs in practice for the treatment and cure of cancers.^[@bibr5-1534735418810799]^ Undoubtedly, patients would seek these treatments when faced with cancers regardless of whether one is a supporter of TCM or not.

Aidi injection is an adjuvant TCM injection commonly used in treatment of lung cancer,^[@bibr6-1534735418810799]^ gastric cancer,^[@bibr7-1534735418810799]^ colorectal cancer,^[@bibr8-1534735418810799]^ liver cancer,^[@bibr9-1534735418810799]^ pancreatic cancer,^[@bibr10-1534735418810799]^ malignant lymphoma,^[@bibr11-1534735418810799]^ and esophageal cancer.^[@bibr12-1534735418810799]^ The ingredients of Aidi injection are extracts from Renshen (Radix Ginseng), Huangqi (Astragaloside), Ciwujia (*Eleutherococcus senticosus*), and Banmao (Cantharidin), all of which are important Chinese herbal medicines, with ability to inhibit cancers and improve immunity.^[@bibr13-1534735418810799][@bibr14-1534735418810799][@bibr15-1534735418810799]-[@bibr16-1534735418810799]^ Previous studies had reported that Aidi injection has the effects of suppressing tumor metastasis, inducing apoptosis of cancer cells, and inhibiting overexpression of drug-resistant proteins induced by chemotherapy.^[@bibr17-1534735418810799],[@bibr18-1534735418810799]^ In addition, the effects of radio-sensitization and altering the expression profiles of microRNAs may be important antitumor mechanisms of Aidi injection.^[@bibr19-1534735418810799],[@bibr20-1534735418810799]^

In recent years, quality of life (QoL) has been recognized as a key component in clinical trial evaluations.^[@bibr21-1534735418810799],[@bibr22-1534735418810799]^ Indeed, the vast majority of clinical trials now report QoL as either primary or secondary endpoints. Therapies that improve QoL in cancer patients are of increasing interest, especially in patients with advanced cancer in whom the scope for improving survival has proved to be limited. Because of the various restrictions in the assessment of QoL in the real-world medical environment, it is important to find surrogate endpoints of QoL as a preliminary assessment.^[@bibr23-1534735418810799]^ Previous research had demonstrated that QoL would be affected by physical function, which is a key component of QoL and is usually assessed objectively by performance status (PS).^[@bibr24-1534735418810799],[@bibr25-1534735418810799]^ In addition, a clinical research study had reported the QoL was related to PS and affected by chemotherapy-related toxicity, and that assessment of those indicators might lead to more effective care for patients.^[@bibr26-1534735418810799]^

After analyzing the progress of research Aidi injection, we found that there is lack of research based on real-world data^[@bibr27-1534735418810799]^ with a large sample size to prove the effect of Aidi injection on QoL, which might be meaningful for clinical decision making. In order to supplement the evidence-based medical evidence, a population-based retrospective cohort study was conducted to investigate whether use of Aidi injection as an adjuvant to chemotherapy might improve QoL in patients with different types of cancer. PS was used as a surrogate endpoint to assess QoL, with assessment of the effect of Aidi injection on relieving chemotherapy-related toxicity as supplementary evidence. The dosage of Aidi injection is determined according to the doctor's advice, which is as follows: The available dosage for all patients is 20 to 100 mL per day and the conventional dosage for adults is 50 to 100 mL per day; 0.9% sodium chloride injection or 5% glucose injection are used for the dilution and it is used synchronously with chemotherapeutic drugs.

Methods {#section2-1534735418810799}
=======

Population {#section3-1534735418810799}
----------

A retrospective cohort study was conducted at the First Affiliated Hospital of Anhui Medical University. Data of patients diagnosed with different types of cancer between January 2014 and June 2017, retrieved from the electronic medical system at the hospital, determined the sample size of this study. Each patient's information on chemotherapy during the period of study and the data of outpatient reexamination after discharge until January 2018 was followed up. The following inclusion and exclusion criteria were adopted for the study. Inclusion criteria: (1) aged 18 years and older, (2) having complete basic information, and (3) receiving at least 1 cycle of chemotherapy. Exclusion criteria: (1) having second primary malignancy, (2) combining multiple therapies or changing chemotherapy methods, (3) missing data, and (4) using Aidi injections 3 months before enrollment or stopping use of Aidi injection during the chemotherapy period.

The information on covariates adjusted for confounding or used for stratification during the baseline period was collected. To control the influence of confounding factors and nonrandom assignment of patients on the results, a logistic regression model was constructed and used as the propensity score. Patients were then propensity score matched 1:1 into the Aidi group and the non-Aidi group. Covariates used for matching were as follows: gender, age, body mass index (BMI), baseline ECOG (Eastern Cooperative Oncology Group) score, tumor type, TNM stage, node metastasis, distant metastasis, prior chemotherapy, prior radiotherapy, comorbidity, chemotherapy regimens, other TCMs, and chemotherapy cycle. The propensity score matching (PSM) algorithm used a 1:1 match with a maximum distance of 0.02. No replacement was allowed, and patients were matched only once. The distribution of propensity score was shown by a mirror histogram, and the symmetrical figure proved the match was sufficient. The balances of matched covariates were evaluated with standardized differences, and less than 10% of differences were considered matched sufficiently.

Ethics {#section4-1534735418810799}
------

The study was approved by the institutional review board of the First Affiliated Hospital of Anhui Medicine University (PJ2017-01-08), and the need for informed consent was waived.

Chemotherapy-Related Toxicity {#section5-1534735418810799}
-----------------------------

The indices of renal function (serum creatinine, SCr) and liver function (alanine aminotransferase, ALT and aspartate aminotransferase, AST) were assessed from routine blood analyses before chemotherapy and 1 week after chemotherapy. The cutoff values of SCr, ALT, and AST were determined according to the reference ranges of markers. Abnormal values (value \>1.5 times the upper limit) before treatment were defined as hepatic insufficiency or renal insufficiency. These indexes were normal before treatment but abnormalities after treatment (value \>1.5 times the upper limit) were considered as injury caused by chemotherapy. Nausea, vomiting, diarrhea, constipation, and allergy were recorded per day according to the progress notes. Myelosuppression was assessed by the changes in counts of white blood cells (WBC), absolute neutrophil count (ANC), and platelets (PLT) before and after chemotherapy. Myelosuppression was divided into 0 to IV grades according to Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE V4.0). WBC: 0, ⩾4.0 × 10^9^/L, I, 3.9-3.0 × 10^9^/L; II, 2.9-2.0 × 10^9^/L; III, 1.9-1.0 × 10^9^/L; IV, \<1.0 × 10^9^/L. ANC: 0, ⩾2.0 × 10^9^/L, I, 1.9-1.5 × 10^9^/L; II, 1.4-1.0 × 10^9^/L; III, 0.9-0.5 × 10^9^/L; IV, \<0.5 × 10^9^/L. PLT: 0, ⩾100 × 10^9^/L; I, 99-75 × 10^9^/L; II, 74-50 × 10^9^/L; III, 49-25 × 10^9^/L; IV, \<25 × 10^9^/L.

Performance Status {#section6-1534735418810799}
------------------

ECOG score was used to assess the PS in patients, which measures PS on a 5-point scale with 0 being "fully active, able to carry on all pre-disease performance without restriction" and 5 indicating that the patient is deceased. The evaluation of ECOG score in patients was performed as follows; ECOG score on day 1 of the chemotherapy cycle and at the end of chemotherapy treatment course were collected, and the changes of scores were considered as changes of PS in patients A decline in ECOG score was defined as improvement in PS. The invariable score was defined as stability and the increase in score was defined as deterioration in PS.

Combined Medication Information {#section7-1534735418810799}
-------------------------------

The combined medication information was analyzed according to the prescription of each patient between 2 groups. The association rule model based on the Apriori algorithm was conducted to explore the rules of combined medication. The most used 14 medicines were included in the model. The intensity of association was divided into strong (link \>50%), medium (link 25%-50%), and weak (link \<25%).

Statistical Analysis {#section8-1534735418810799}
--------------------

The categorical variables among the Aidi group and control group were evaluated by chi-square or Fisher's exact test and continuous variables were analyzed by *t* test.

Logistic regression analysis was conducted to explore the independent influence factors associated with PS. A multivariate analysis was performed with statistically significant factors from the univariate analysis (*P* \< .05). The difference in improvement rate of PS among the patients with different characteristics in the Aidi group was also compared by logistic regression analysis.

The stratified analysis of difference in improvement rate of PS between the Aidi group and the non-Aidi group was shown in the form of forest plots. When the 95% confidence interval (CI) upper and lower limits of odds ratios (ORs) were \>1, that is, in the forest map, the 95% CI horizontal line did not intersect the invalid vertical line, and the horizontal line fell to the right side of the invalid line, it could be considered that the improvement rate of PS in the Aidi group is greater than that in the control group. The stratified analysis of association between the dosage of Aidi injection and QoL was shown in tabular form. Taking the non-Aidi group as the reference, the effects of different dosages of Aidi injection on PS were compared in the subgroup.

All analyses described above were performed using SPSS version 22.0 software (IBM Corp, Armonk, NY, USA).

Results {#section9-1534735418810799}
=======

Patient Characteristics {#section10-1534735418810799}
-----------------------

A total of 2122 Aidi injection users and 2950 non-Aidi injection users among cancer patients identified between January 2014 and June 2017 ([Table 1](#table1-1534735418810799){ref-type="table"}) were enrolled in our study. A PSM was then performed and 5072 cancer patients were 1:1 matched, comprising an Aidi and non-Aidi group. A total of 3200 cancer patients were eventually included in the analysis, and the baseline characteristics after PSM are shown in [Table 2](#table2-1534735418810799){ref-type="table"}. After matching, covariates were well balanced with no significant differences in demographic or tumor-related variables between the 2 groups. Propensity score with mirror histograms and standardized differences before and after matching were shown in [Figures 1A](#fig1-1534735418810799){ref-type="fig"}-[B](#fig1-1534735418810799){ref-type="fig"} and [2](#fig2-1534735418810799){ref-type="fig"}.

###### 

Characteristics of Patients Before Propensity Score Matching.

![](10.1177_1534735418810799-table1)

                                           Aidi Injection Used                               
  ---------------------------------------- --------------------- ------------- ------ ------ ------------
  Gender                                                                                     **\<.001**
   Female                                  1168                  39.6          995    46.9   
   Male                                    1782                  60.4          1127   53.1   
  Age, years                                                                                 
   ⩽60s                                    1350                  45.8          1090   51.4   **\<.001**
   \>60                                    1600                  54.2          1032   48.6   
   Mean ± SD                               59.7±10.8             59.2 ± 11.6   .296          
  Body mass index, kg/m^2^                                                                   
   \<18.5                                  439                   14.9          346    16.3   **.146**
   18.5-24                                 1962                  66.5          1419   66.9   
   \>24                                    549                   18.6          357    16.8   
  Tumor type                                                                                 **\<.001**
   Gastric cancer                          1482                  50.2          1022   48.2   
   Lung cancer                             636                   21.6          372    17.5   
   Breast cancer                           350                   11.9          326    15.4   
   Colorectal cancer                       270                   9.2           245    11.5   
   Cardias and esophageal cancer           119                   4.0           87     4.1    
   Hepatobiliary cancer                    34                    1.2           24     1.1    
   Ovarian cancer                          59                    2.0           46     2.2    
  TNM stage                                                                                  .163
   I-II                                    444                   15.1          350    16.5   
   III-IV                                  2506                  84.9          1772   83.5   
  Node metastasis                                                                            **\<.001**
   Negative                                1639                  55.6          1325   62.4   
   Positive                                1311                  44.4          797    37.6   
  Distant metastasis                                                                         **\<.001**
   Negative                                1771                  60.0          1454   68.5   
   Positive                                1179                  40.0          668    31.5   
  Prior chemotherapy                                                                         **\<.001**
   No                                      1742                  59.1          1041   49.1   
   Yes                                     1208                  40.9          1081   50.9   
  Prior radiotherapy                                                                         **\<.001**
   No                                      2792                  94.6          2096   98.8   
   Yes                                     158                   5.4           26     1.2    
  ECOG score                                                                                 **.038**
   0-1                                     2822                  95.7          2003   94.4   
   ⩾2                                      158                   5.4           119    5.6    
  Comorbidity                                                                                
   Hypertension                            385                   13.1          268    12.6   .659
   Renal insufficiency                     33                    1.1           66     3.1    **\<.001**
   Hepatic insufficiency                   495                   16.8          375    17.7   .406
   Diabetes                                136                   4.6           111    5.2    .311
  Chemotherapy regimen                                                                       **\<.001**
   Platinum and fluorouracil based         1370                  46.4          1006   47.4   
   Platinum and pemetrexed based           215                   7.3           166    7.8    
   Irinotecan and fluorouracil based       266                   9.0           201    9.5    
   Platinum and taxane based               681                   23.1          463    21.8   
   Cyclophosphamide and adriamycin based   157                   5.3           157    7.4    
   Targeted therapy and others regimen     261                   8.8           129    6.1    
  Other Chinese medicine                                                                     
   ShenqiFuzheng injection                 827                   28.0          756    35.6   **\<.001**
   Glycopeptide injection                  764                   25.9          645    30.4   **\<.001**
   Kushen injection                        457                   15.5          292    13.8   .087
   Shenmai Injection                       271                   9.2           168    7.9    .113
   DiyuShengbai tablet                     161                   5.5           143    6.7    .058
  Chemotherapy cycles                                                                        **\<.001**
   1-3                                     1777                  60.2          1402   66.1   
   \>3                                     1173                  39.8          720    33.9   

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

Boldfaced *P* values are statistically significant.

###### 

Characteristics of Patients After Propensity Score Matching.

![](10.1177_1534735418810799-table2)

                                           Aidi Injection Used                                
  ---------------------------------------- --------------------- ------------- ------- ------ ------
  Gender                                                                                      .414
   Female                                  706                   44.1          729     45.6   
   Male                                    894                   55.9          871     55.4   
  Age, years                                                                                  
   ⩽60                                     791                   49.4          784     49.0   .805
   \>60                                    809                   50.6          816     51.0   
   Mean ± SD                               60.7 ± 10.4           60.5 ± 11.1   .8085          
  Body mass index, kg/m^2^                                                                    
   \<18.5                                  252                   15.8          260     16.2   .665
   18.5-24                                 1105                  69.1          1082    67.6   
   \>24                                    243                   15.2          258     16.1   
  Tumor type                                                                                  .101
   Gastric cancer                          798                   49.9          815     50.9   
   Lung cancer                             288                   18.0          294     18.4   
   Breast cancer                           212                   13.2          238     14.9   
   Colorectal cancer                       154                   9.6           108     6.8    
   Cardiac and esophageal cancer           86                    5.4           77      4.8    
   Hepatobiliary cancer                    20                    1.2           23      1.4    
   Ovarian cancer                          42                    2.6           45      2.8    
  TNM stage                                                                                   .825
   I-II                                    274                   17.1          278     17.4   
   III-IV                                  1326                  82.9          1322    82.6   
  Node metastasis                                                                             .689
   Negative                                979                   61.2          990     61.9   
   Positive                                621                   38.8          610     38.1   
  Distant metastasis                                                                          .244
   Negative                                1054                  65.9          1085    67.8   
   Positive                                546                   34.1          515     32.2   
  Prior chemotherapy                                                                          .524
   No                                      830                   51.9          812     50.7   
   Yes                                     770                   48.1          788     49.9   
  Prior radiotherapy                                                                          .351
   No                                      1582                  98.9          1576    98.5   
   Yes                                     18                    1.1           24      1.5    
  ECOG score                                                                                  .317
   0-1                                     1504                  94.0          1517    94.8   
   ⩾2                                      96                    6.0           83      5.2    
  Comorbidity                                                                                 
   Hypertension                            197                   12.3          204     12.8   .709
   Renal insufficiency                     24                    1.5           24      1.5    .999
   Hepatic insufficiency                   262                   16.4          256     16.0   .773
   Diabetes                                73                    4.6           75      4.7    .866
  Chemotherapy regimen                                                                        
   Platinum and fluorouracil based         770                   48.2          773     48.2   .585
   Platinum and pemetrexed based           83                    5.2           96      6.0    
   Irinotecan and fluorouracil based       148                   9.3           136     8.5    
   Platinum and taxane based               392                   24.5          413     25.8   
   Cyclophosphamide and adriamycin based   110                   6.9           102     6.4    
   Targeted therapy and others regimen     96                    6.0           80      5.0    
  Other Chinese medicine                                                                      
   ShenqiFuzheng injection                 503                   31.4          497     31.1   .819
   Glycopeptide injection                  424                   26.5          433     27.1   .719
   Kushen injection                        255                   15.9          268     16.8   .534
   Shenmai Injection                       123                   7.7           123     7.7    .999
   DiyuShengbai tablet                     50                    3.1           65      4.1    .154
  Chemotherapy cycles                                                                         
   1-3                                     1049                  65.6          1055    65.9   .823
   \>3                                     551                   34.4          545     34.1   

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

![Mirror histograms (A) before propensity score matching and (B) after propensity score matching.](10.1177_1534735418810799-fig1){#fig1-1534735418810799}

![Standardized differences.](10.1177_1534735418810799-fig2){#fig2-1534735418810799}

Chemotherapy-Related Toxicity {#section11-1534735418810799}
-----------------------------

As shown in [Table 3](#table3-1534735418810799){ref-type="table"}, the incidence rate of damage to renal and liver function, nausea, vomiting, and diarrhea in the Aidi group was significantly lower than that in the control group both in short and long chemotherapy cycles. As shown in [Table 4](#table4-1534735418810799){ref-type="table"}, the combination of Aidi injection and chemotherapy significantly decreased the incidence rate of chemotherapy-related leucopenia, neutropenia, and thrombocytopenia compared with chemotherapy alone (*P* \< .001, *P* = .033, and *P* \< .001, respectively).

###### 

Chemotherapy-Related Toxicity.

![](10.1177_1534735418810799-table3)

                      Aidi injection used                        
  ------------------- --------------------- ------ ------ ------ ------------
  Short cycle (1-3)   1049                  65.6   1055   65.9   
   AST elevation      114                   10.9   80     7.6    **.009**
   ALT elevation      162                   15.4   96     9.1    **\<.001**
   CR elevation       30                    2.9    16     1.5    **.035**
   Nausea, vomiting   463                   43.9   367    34.8   **\<.001**
   Diarrhea           93                    8.9    52     4.9    **\<.001**
   Constipation       69                    6.6    54     5.1    .154
   Allergy            41                    3.9    38     3.6    .711
  Long cycle (\>3)    551                   34.4   545    34.1   
   AST elevation      99                    17.9   74     13.6   **.046**
   ALT elevation      114                   20.7   83     15.2   **.019**
   CR elevation       49                    8.5    30     5.5    **.030**
   Nausea, vomiting   293                   53.2   227    41.7   **\<.001**
   Diarrhea           74                    13.4   42     7.7    **.002**
   Constipation       51                    9.2    39     7.2    .205
   Allergy            55                    6.4    26     4.8    .254

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; CR creatinine.

Boldfaced *P* values values are statistically significant.

###### 

Chemotherapy-Related Hematological Toxicity.

![](10.1177_1534735418810799-table4)

                                     Grade                                                        
  ------------------ --------------- ------------- ------------ ------------ ---------- --------- ------------
  Leucopenia                                                                                      **\<.001**
                     Aidi group      1221 (76.3)   166 (10.4)   174 (10.8)   38 (2.4)   1 (0.1)   
                     Control group   1110 (69.4)   232 (14.5)   218 (13.6)   35 (2.2)   5 (0.3)   
  Neutropenia                                                                                     **.033**
                     Aidi group      1248 (78.0)   153 (9.6)    149 (9.3)    47 (2.9)   3 (0.2)   
                     Control group   1207 (75.4)   183 (11.4)   169 (10.6)   32 (2.0)   9 (0.6)   
  Thrombocytopenia                                                                                **\<.001**
                     Aidi group      1448 (90.5)   97 (6.1)     48 (3.0)     7 (0.4)    0 (0.0)   
                     Control group   1365 (85.3)   133 (8.3)    77 (4.8)     17 (1.1)   8 (0.5)   

Boldfaced *P* values are statistically significant.

Performance Status {#section12-1534735418810799}
------------------

The number of patients with decreased ECOG score (ie, improved PS) for those who underwent Aidi injection combined with chemotherapy was 137 while it was 48 for those who underwent chemotherapy alone, with a significant difference. The patients with increasing ECOG score (ie, worse PS) in the Aidi group were significantly less than those in the control group. Overall, there was a significant improvement of PS in patients in the Aidi group ([Table 5](#table5-1534735418810799){ref-type="table"}).

###### 

Changes in Performance Status.

![](10.1177_1534735418810799-table5)

                  Aidi Injection Used                        
  --------------- --------------------- ------ ------ ------ ------------
  Deterioration   59                    3.7    6      0.4    **\<.001**
  Stabilization   1493                  93.3   1457   91.1   **\<.001**
  Improvement     48                    3.0    137    8.5    **\<.001**

Boldfaced *P* values are statistically significant.

The results of the univariate analysis are shown in [Table 6](#table6-1534735418810799){ref-type="table"}. Patients with node metastasis (*P* \< .001, OR 0.4, 95% CI 0.3-0.6), distant metastasis (*P* \< .001, OR 0.3, 95% CI 0.2-0.4), worse baseline ECOG score (*P* = .045, OR 0.4, 95% CI 0.1-1.0), and hepatic insufficiency (*P* \< .001, OR 0.2, 95% CI 0.1-0.5) were significantly associated with worse PS. On the contrary, Aidi injection (*P* \< .001, OR 2.9, 95% CI 2.1-4.1) and long chemotherapy cycles (*P* \< .001, OR 2.1, 95% CI 1.5-2.8) were the influence factors associated with better PS. Patients with lung cancer, breast cancer, cardia and esophageal cancer, and ovarian cancer had better improvement rate of PS compared with patients with gastric cancer. According to the results of multivariate analysis, Aidi injection was a significant independent factor of improving PS after adjusting for the confounding factors (*P* \< .001, OR 3.4, 95% CI 2.4-4.8). Other independent factors were tumor types, node metastasis, distant metastasis, baseline ECOG score, hepatic insufficiency, and chemotherapy cycle.

###### 

Logistic Regression Model With Odds Ratios (ORs) and 95% CI of Improvement Rate of Performance Status.

![](10.1177_1534735418810799-table6)

                                           Univariable     Multivariable                                           
  ---------------------------------------- --------------- --------------- ------------ --------------- ---------- ------------
  Gender                                                                                                           
   Female                                  \[reference\]                                                           
   Male                                    1.2             0.9-1.6         .294                                    
  Age, years                                                                                                       
   ⩽60                                     \[reference\]                                                           
   \>60                                    0.8             0.6-1.2         .291                                    
  Body mass index, kg/m^2^                                                                                         
   \<18.5                                  \[reference\]                                                           
   18.5-24                                 0.8             0.5-1.2         .264                                    
   \>24                                    1.3             0.8-2.1         .303                                    
  Tumor type                                                                                                       
   Gastric cancer                          \[reference\]                                \[reference\]              
   Lung cancer                             3.1             2.1-4.6         **\<.001**   3.7             2.3-5.9    **\<.001**
   Breast cancer                           3.0             1.9-4.6         **\<.001**   3.1             1.9-5.1    **\<.001**
   Colorectal cancer                       1.4             0.7-2.6         .371         0.3             0.1-1.0    .060
   Cardiac and esophageal cancer           2.7             1.4-5.1         **.002**     2.5             1.3-4.8    **.007**
   Hepatobiliary cancer                    2.2             0.7-7.3         .200         2.6             0.7-9.1    .135
   Ovarian cancer                          5.8             3.1-10.9        **\<.001**   6.8             3.4-13.7   **\<.001**
  TNM stage                                                                                                        
   I-II                                    \[reference\]                                                           
   III-IV                                  1.0             0.7-1.4         .848                                    
  Node metastasis                                                                                                  
   Negative                                \[reference\]                                \[reference\]              
   Positive                                0.4             0.3-0.6         **\<.001**   0.4             0.3-0.6    **\<.001**
  Distant metastasis                                                                                               
   Negative                                \[reference\]                                \[reference\]              
   Positive                                0.3             0.2-0.4         **\<.001**   0.2             0.2-0.4    **\<.001**
  Prior chemotherapy                                                                                               
   No                                      \[reference\]                                                           
   Yes                                     0.9             0.7-1.3         .683                                    
  Prior radiotherapy                                                                                               
   No                                      \[reference\]                                                           
   Yes                                     2.2             0.9-5.8         .094                                    
  ECOG score                                                                                                       
   0-1                                     \[reference\]                                \[reference\]              
   ⩾2                                      0.4             0.1-1.0         **.045**     0.3             0.1-0.9    **.024**
  Hypertension                                                                                                     
   No                                      \[reference\]                                                           
   Yes                                     1.4             0.9-2.1         .121                                    
  Renal insufficiency                                                                                              
   No                                      \[reference\]                                                           
   Yes                                     1.1             0.3-3.5         .918                                    
  Hepatic insufficiency                                                                                            
   No                                      \[reference\]                                \[reference\]              
   Yes                                     0.2             0.1-0.5         **\<.001**   0.5             0.2-1.0    **.037**
  Diabetes                                                                                                         
   No                                      \[reference\]                                                           
   Yes                                     0.9             0.4-1.9         .793                                    
  Chemotherapy regimen                                                                                             
   Platinum and fluorouracil based         \[reference\]                                \[reference\]              
   Platinum and pemetrexed based           2.3             1.3-4.0         **.003**     1.2             0.6-2.3    .589
   Irinotecan and fluorouracil based       1.0             0.5-1.8         .928         1.3             0.7-2.5    .444
   Platinum and taxane based               1.6             0.8-3.0         .161         1.7             0.9-3.4    .127
   Cyclophosphamide and adriamycin based   1.9             1.1-3.4         **.019**     1.1             0.6-2.0    .870
   Targeted therapy and others regimen     1.8             1.2-2.5         **.002**     1.2             0.8-1.8    .353
  Other Chinese medicine                                                                                           
   ShenqiFuzheng injection                                                                                         
    No                                     \[reference\]                                                           
    Yes                                    1.1             0.8-1.5         .477                                    
   Glycopeptide injection                                                                                          
    No                                     \[reference\]                                                           
    Yes                                    1.0             0.7-1.4         .965                                    
   Kushen injection                                                                                                
    No                                     \[reference\]                                                           
    Yes                                    1.0             0.7-1.5         .975                                    
   Shenmai injection                                                                                               
    No                                     \[reference\]                                                           
    Yes                                    1,0             0.6-1.8         .878                                    
   DiyuShengbai tablet                                                                                             
    No                                     \[reference\]                                                           
    Yes                                    1.8             1.0-3.5         .067                                    
  Chemotherapy cycles                                                                                              
   1-3                                     \[reference\]                                \[reference\]              
   \>3                                     2.1             1.5-2.8         **\<.001**   2.8             2.1-3.9    **\<.001**
  Aidi injection used                                                                                              
   No                                      \[reference\]                                \[reference\]              
   Yes                                     2.9             2.1-4.1         **\<.001**   3.4             2.4-4.8    **\<.001**

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

Boldfaced *P* values are statistically significant.

In a stratified analysis ([Figure 3](#fig3-1534735418810799){ref-type="fig"}), the result indicated that Aidi injection led to a durable improvement in PS across almost all subgroups Stratified by gender, age, TNM stage, node metastasis or not, prior chemotherapy or not, baseline ECOG score, chemotherapy regimens, other Chinese medicines and different chemotherapy cycles, the Aidi group showed higher improvement rate of PS than that in the control group. In subgroups of patients with hepatobiliary cancer, distant metastasis and comorbidity (hypertension, renal insufficiency, hepatic insufficiency, and diabetes), the improvement rate of PS showed no statistical difference between the 2 groups. However, the ORs from almost all subgroups suggested that cancer patients receiving chemotherapy might benefit from Aidi injection.

![Stratified analysis.](10.1177_1534735418810799-fig3){#fig3-1534735418810799}

The difference in improvement rate of PS among the patients with different characteristics in the Aidi group is shown in [Table 7](#table7-1534735418810799){ref-type="table"}. Aidi injection was shown to be less effective in patients with advanced age (\>60 years), node metastasis, distant metastasis, worse baseline ECOG score compared to patients with younger age (⩽60 years), no node metastasis, no distant metastasis and better baseline ECOG score. In addition, Aidi injection had better effects for patients with lung cancer, breast cancer, cardia and esophageal cancer and ovarian cancer compared to patients with gastric cancer, colorectal cancer, and hepatobiliary cancer. It was worth noting that Aidi injection combined with platinum and pemetrexed or taxane should be more beneficial to patients in comparison with other chemotherapy regimens. From the perspective of treatment cycles, patients with long chemotherapy cycles might have a higher improvement rate of PS.

###### 

Odds Ratios (ORs) and 95% CI of Performance Status Benefit Associated With Aidi Injection for Patients With Different Characteristics.

![](10.1177_1534735418810799-table7)

                                                      Aidi User (N = 1600)                                                      
  --------------------------------------------------- ---------------------- ---------- ------------ --------------- ---------- ------------
  Gender                                                                                                                        
   Female                                             \[reference\]                                  \[reference\]              
   Male                                               1.4                    1.0-2.0    .064         1.1             0.7-1.7    .798
  Age, years                                                                                                                    
   ⩽60                                                \[reference\]                                  \[reference\]              
   \>60                                               0.8                    0.5-1.1    .121         0.5             0.4-0.8    **.004**
  Body mass index, kg/m^2^                                                                                                      
   \<18.5                                             \[reference\]                                  \[reference\]              
   18.5-24                                            0.8                    0.5-1.2    .264         1.0             0.6-1.7    .932
   \>24                                               1.3                    0.8-2.1    .303         1.5             0.8-2.9    .242
  Tumor type                                                                                                                    
   Gastric cancer                                     \[reference\]                                  \[reference\]              
   Lung cancer                                        2.6                    1.6-4.2    **\<.001**   2.4             1.3-4.4    **.004**
   Breast cancer                                      2.6                    1.5-4.2    **\<.001**   2.1             1.0-4.2    **.041**
   Colorectal cancer                                  1.9                    0.9-3.9    **.080**     1.5             0.7-3.4    .290
   Cardiac and esophageal cancer                      2.9                    1.4-6.0    **.005**     3.3             1.4-7.3    **.004**
   Hepatobiliary cancer                               1.6                    0.4-7.0    .537         2.1             0.4-9.8    .367
   Ovarian cancer                                     6.4                    3.1-13.2   **\<.001**   6.9             2.8-17.2   **\<.001**
  TNM stage                                                                                                                     
   I-II                                               \[reference\]                                  \[reference\]              
   III-IV                                             1.0                    0.6-1.6    .948         1.5             0.8-2.6    .188
  Node metastasis                                                                                                               
   Negative                                           \[reference\]                                  \[reference\]              
   Positive                                           0.4                    0.3-0.6    **\<.001**   0.4             0.3-0.7    **\<.001**
  Distant metastasis                                                                                                            
   Negative                                           \[reference\]                                  \[reference\]              
   Positive                                           0.2                    0.1-0.4    **\<.001**   0.2             0.1-0.3    **\<.001**
  Prior chemotherapy                                                                                                            
   No                                                 \[reference\]                                  \[reference\]              
   Yes                                                1.0                    0.7-1.4    .924         0.9             0.6-1.3    .583
  Prior radiotherapy                                                                                                            
   No                                                 \[reference\]                                  \[reference\]              
   Yes                                                2.9                    1.1-7.8    **.039**     1.0             0.7-1.6    .874
  ECOG score                                                                                                                    
   0-1                                                \[reference\]                                  \[reference\]              
   ⩾2                                                 0.4                    0.1-1.2    **.109**     0.2             0.1-0.8    **.024**
  Hypertension                                                                                                                  
   No                                                 \[reference\]                                  \[reference\]              
   Yes                                                0.7                    0.4-1.3    .235         1.1             0.6-2.3    .687
  Renal insufficiency                                                                                                           
   No                                                 \[reference\]                                  \[reference\]              
   Yes                                                0.5                    0.1-3.4    .447         0.5             0.1-4.3    .499
  Hepatic insufficiency                                                                                                         
   No                                                 \[reference\]                                  \[reference\]              
   Yes                                                0.3                    0.1-0.6    **\<.001**   0.5             0.2-0.8    **\<.001**
  Diabetes                                                                                                                      
   No                                                 \[reference\]                                  \[reference\]              
   Yes                                                0.4                    0.1-1.4    .158         0.5             0.1-1.9    .336
  Chemotherapy regimen                                                                                                          
   Platinum and fluorouracil based                    \[reference\]                                  \[reference\]              
   Platinum and pemetrexed based                      3.0                    1.6-5.6    **\<.001**   2.4             1.1-5.4    **.037**
   Irinotecan and fluorouracil based                  1.1                    0.5-2.4    .731         1.2             0.5-2,7    .662
   Platinum and taxane based                          2.4                    1.1-4.9    **.021**     2.9             1.3-6.5    **.010**
   Cyclophosphamide and adriamycin based              2.3                    1.2-4.5    **.012**     1.2             0.5-2.6    .728
   Targeted therapy and others regimen                2.0                    1.3-3.0    **.002**     1.4             0.9-2.4    .160
  Other Chinese medicine                                                                                                        
   ShenqiFuzheng injection                                                                                                      
    No                                                \[reference\]                                  \[reference\]              
    Yes                                               1.1                    0.8-1.5    .477         1.2             0.8-1.9    .389
   Glycopeptide injection                                                                                                       
    No                                                \[reference\]                                  \[reference\]              
    Yes                                               1.0                    0.7-1.4    .965         1.1             0.7-1.7    .756
   Kushen injection                                                                                                             
    No                                                \[reference\]                                  \[reference\]              
    Yes                                               1.0                    0.7-1.5    .975         1.0             0.6-1.7    .899
   Shenmai injection                                                                                                            
    No                                                \[reference\]                                  \[reference\]              
    Yes                                               1.0                    0.6-1.8    .878         1.4             0.7-2.8    .365
   DiyuShengbai tablet                                                                                                          
    No                                                \[reference\]                                  \[reference\]              
    Yes                                               1.8                    1.0-3.5    .067         1.6             0.4-4.0    .328
  Chemotherapy cycles                                                                                                           
   1-3                                                \[reference\]                                  \[reference\]              
   \>3                                                2.2                    1.5-3.1    **\<.001**   3.0             2.0-4.6    **\<.001**
  Dosage                                                                                                                        
   No Aidi use                                        \[reference\]                                  \[reference\]              
   Less than conventional dosage (20-50 mL per day)   2.3                    1.2-4.4    **.014**     2.8             1.4-5.6    **.004**
   Conventional dosage (50-100 mL per day)            3.1                    2.2-4.4    **\<.001**   3.6             2.5-5.1    **\<.001**

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

Boldfaced *P* values are statistically significant.

Effect of Different Dosage of Aidi Injection {#section13-1534735418810799}
--------------------------------------------

According to the instructions, the conventional dosage of Aidi injection for adults is 50 to 100 mL per day. Yet in our research, a subset of patients had used Aidi injection at less than conventional dosage in actual clinical use (20-50 mL). To understand the association between the dosages of Aidi injection and QoL, we further classified patients into three subgroups (conventional dosage group, less than conventional dosage group and non-Aidi group) according to the actual dosage of Aidi injection. Compared with non-Aidi injection, we found that the adjusted OR for PS is 2.8 (95% CI 1.4-5.6; *P* = .004) among the patients who used Aidi injection at less than the conventional dosage and 3.6 (95% CI 2.5-5.1; *P* \< .001) in the conventional dosage group, which suggested that conventional dosage of Aidi injection might have had a better effect on PS ([Table 7](#table7-1534735418810799){ref-type="table"}). According to this result, a subgroup analysis was then performed to further investigate the effect of different dosage on patients with different characteristics. As showed in [Table 8](#table8-1534735418810799){ref-type="table"}, in almost all subgroups, the conventional dosage of Aidi injection showed more benefit in PS on patients compared to the other 2 groups. Besides, in comparison with the non-Aidi group, using the conventional dosage of Aidi injection decreased the incidence rate of all types of chemotherapy-related toxicity. However, using Aidi injection with less than conventional dosage had a poor effect on reducing incidence rate of chemotherapy-related toxicity (only showing significant difference in leukopenia compared with the non-Aidi group) ([Table 9](#table9-1534735418810799){ref-type="table"}). In addition, the proportion of patients with improved PS was higher in the conventional dosage group, which was statistically different from the other 2 groups ([Table 9](#table9-1534735418810799){ref-type="table"}). These results revealed that conventional dosage of Aidi injection had a better effect in improving PS and decreasing toxicity, that is, it was more beneficial to QoL of cancer patients.

###### 

Odds Ratios (ORs) and 95% CI of Performance Status Benefit Associated With Different Dosage of Aidi Injection in the Stratified Analysis.

![](10.1177_1534735418810799-table8)

                                           Non-Aidi Use (N = 1600)   Aidi Use                                         
  ---------------------------------------- ------------------------- ------------------ ------------ ---------------- ------------
  Variable                                                                                                            
  Gender                                                                                                              
   Female                                  \[reference\]             2.0 (0.6-5.9)      .238         2.2 (1.7-2.9)    **\<.001**
   Male                                    \[reference\]             1.2 (1.1-1.6)      **\<.001**   1.5 (1.2-1.8)    **\<.001**
  Age, years                                                                                                          
   ⩽60                                     \[reference\]             1.5 (1.2-1.9)      **\<.001**   2.0 (1.6-2.6)    **\<.001**
   \>60                                    \[reference\]             1.7 (0.6-4.5)      .297         1.6 (1.2-2.0)    **\<.001**
  Body mass index, kg/m^2^                                                                                            
   \<18.5                                  \[reference\]             4.4 (0.8-25.3)     .094         2.9 (1.5-5.0)    **\<.001**
   18.5-24                                 \[reference\]             2.6 (1.3-5.4)      **.009**     1.5 (1.2-1.8)    **\<.001**
   \>24                                    \[reference\]             1.3 (0.9-4.3)      .252         2.1 (1.4-3.2)    **\<.001**
  Tumor type                                                                                                          
   Gastric cancer                          \[reference\]             6.0 (2.4-15.0)     **\<.001**   2.1 (1.4-2.9)    **\<.001**
   Lung cancer                             \[reference\]             1.1 (0.2-4.9)      .912         1.4 (1.0-1.9)    **.029**
   Breast cancer                           \[reference\]             1.6 (1.1-2.3)      **\<.001**   1.9 (1.3-2.8)    **.002**
   Colorectal cancer                       \[reference\]             1.4 (0.9-3.3)      .792         1.8 (1.1-3.6)    **\<.001**
   Cardiac and esophageal cancer           \[reference\]             12.1 (0.9-143.0)   .057         3.0 (1.0-8.9)    **.042**
   Hepatobiliary cancer                    \[reference\]             1.3 (0.6-9.7)      .891         0.8 (0.3-1.8)    0.591
   Ovarian cancer                          \[reference\]             2.2 (1.6-3.3)      **.042**     2.5 (1.1-5.6)    **.026**
  TNM stage                                                                                                           
   I-II                                    \[reference\]             2.1 (0.4-10.2)     .357         1.7 (1.1-2.5)    **.009**
   III-IV                                  \[reference\]             1.3 (1.1-1.7)      **\<.001**   1.8 (1.5-2.2)    **\<.001**
  Node metastasis                                                                                                     
   Negative                                \[reference\]             1.6 (1.4-1.9)      **\<.001**   1.7 (1.4-2.1)    **\<.001**
   Positive                                \[reference\]             0.9 (0.1-7.4)      .936         1.9 (1.3-2.8)    **\<.001**
  Distant metastasis                                                                                                  
   Negative                                \[reference\]             1.3 (1.2-1.6)      **.018**     1.8 (1.5-2.2)    **\<.001**
   Positive                                \[reference\]             1.3 (0.2-11.0)     .782         1.4 (0.9-2.2)    .145
  Prior chemotherapy                                                                                                  
   No                                      \[reference\]             1.4 (0.5-3.8)      .476         1.7 (1.3-2.1)    **\<.001**
   Yes                                     \[reference\]             3.7 (1.5-9.2)      **.004**     1.9 (1.5-2.5)    **\<.001**
  ECOG score                                                                                                          
   0-1                                     \[reference\]             1.4 (1.3-1.7)      **\<.001**   1.8 (1.5-2.1)    **\<.001**
   ⩾2                                      \[reference\]             0.9 (0.3-1.6)      .496         1.2 (0.5-2.6)    .733
  Hypertension                                                                                                        
   No                                      \[reference\]             1.4 (1.2-1.9)      **\<.001**   1.9 (1.6-2.3)    **\<.001**
   Yes                                     \[reference\]             2.0 (0.4-9.7)      .395         1.3 (0.9-1.9)    .181
  Renal insufficiency                                                                                                 
   No                                      \[reference\]             1.4 (1.3-1.7)      **\<.001**   1.8 (1.5-2.1)    **\<.001**
   Yes                                     \[reference\]             0.4 (0.2-0.8)      .797         0.8 (0.2-2.8)    .731
  Hepatic insufficiency                                                                                               
   No                                      \[reference\]             1.4 (1.3-4.7)      **.008**     1.8 (1.5-2.2)    **\<.001**
   Yes                                     \[reference\]             1.1(0.9-2.9)       .594         1.4 (0.8-2.6)    .265
  Diabetes                                                                                                            
   No                                      \[reference\]             1.5 (1.3-1.8)      **\<.001**   1.9 (1.6-2.2)    **\<.001**
   Yes                                     \[reference\]             0.6 (0.4-1.9)      .395         0.8 (0.4-1.6)    .484
  Chemotherapy regimen                                                                                                
   Platinum and fluorouracil based         \[reference\]             3.5 (1.4-8.7)      **.006**     1.8 (1.4-2.4)    **\<.001**
   Platinum and pemetrexed based           \[reference\]             6.7 (1.0-46.0)     .054         2.2 (1.1-4.2)    **.018**
   Irinotecan and fluorouracil based       \[reference\]             3.2 (0.6-17.6)     .185         1.2 (1.0-1.8)    **.042**
   Platinum and taxane based               \[reference\]             2.8 (1.1-4.9)      **.045**     3.2 (1.1-9.2)    **.033**
   Cyclophosphamide and adriamycin based   \[reference\]             1.7 (1.3-3.4)      **.037**     2.5 (1.2-5.6)    **.019**
   Targeted therapy and others regimen     \[reference\]             0.5 (0.1-4.1)      .542         1.6 (1.2-2.1)    **.002**
  Other Chinese medicine                                                                                              
  ShenqiFuzheng injection                                                                                             
   No                                      \[reference\]             1.4 (1.2-1.7)      **\<.001**   1.7 (1.4-2.1)    **\<.001**
   Yes                                     \[reference\]             1.8 (0.8-4.2)      .152         1.9 (1.4-2.6)    **\<.001**
  Glycopeptide injection                                                                                              
   No                                      \[reference\]             2.4 (1.1-5.0)      **.026**     1.7 (1.4-2.1)    **\<.001**
   Yes                                     \[reference\]             2.1 (0.6-7.5)      .275         1.9 (1.3-2.6)    **\<.001**
  Kushen injection                                                                                                    
   No                                      \[reference\]             1.9 (0.9-4.1)      .083         1.8 (1.5-2.2)    **\<.001**
   Yes                                     \[reference\]             5.5 (1.3-22.3)     .018         1.5 (1.1-2.2)    **.038**
  Shenmai injection                                                                                                   
   No                                      \[reference\]             1.5 (1.2-1.7)      **\<.001**   1.7 (1.4-2.0)    **\<.001**
   Yes                                     \[reference\]             3.2 (1.6-7.2)      .042         3.9 (1.4-10.9)   **.009**
  DiyuShengbai tablet                                                                                                 
   No                                      \[reference\]             1.3 (1.2-1.7)      **.011**     1.7 (1.5-2.1)    **\<.001**
   Yes                                     \[reference\]             1.7 (1.2-4.8)      .023         2.5 (1.1-7.2)    **\<.001**
  Chemotherapy cycle                                                                                                  
   1-3                                     \[reference\]             1.3 (0.4-3.8)      .631         1.7 (1.4-2.2)    **\<.001**
   \>3                                     \[reference\]             4.1 (1.7-9.6)      **.001**     1.8 (1.4-2.3)    **\<.001**

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

Boldfaced *P* values are statistically significant.

###### 

Effects of Different Dosage of Aidi Injection on Chemotherapy-Related Toxicity and Performance Status.

![](10.1177_1534735418810799-table9)

                       Non-Aidi Group   Aidi Group                                                           
  -------------------- ---------------- -------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------
  Toxicity                                                                                                   
   AST elevation       213 (13.3)       27 (9.6)                                                             127 (8.9)^[a](#table-fn15-1534735418810799){ref-type="table-fn"},[b](#table-fn16-1534735418810799){ref-type="table-fn"}^
   ALT elevation       276 (17.3)       31 (16.9)                                                            152 (10.7)^[a](#table-fn15-1534735418810799){ref-type="table-fn"},[b](#table-fn16-1534735418810799){ref-type="table-fn"}^
   CR elevation        79 (4.9)         8 (4.4)                                                              36 (2.7)^[b](#table-fn16-1534735418810799){ref-type="table-fn"}^
   Nausea, vomiting    756 (47.2)       67 (36.6)                                                            527 (37.0)^[a](#table-fn15-1534735418810799){ref-type="table-fn"},[b](#table-fn16-1534735418810799){ref-type="table-fn"}^
   Diarrhea            167 (10.4)       18 (8.2)                                                             76 (5.4)^[a](#table-fn15-1534735418810799){ref-type="table-fn"},[b](#table-fn16-1534735418810799){ref-type="table-fn"}^
   Constipation        120 (7.5)        16 (8.7)                                                             77 (5.3)^[a](#table-fn15-1534735418810799){ref-type="table-fn"}^
   Allergy             96 (6.0)         8 (4.4)                                                              56 (4.0)^[a](#table-fn15-1534735418810799){ref-type="table-fn"}^
   Leucopenia          490 (30.6)       41 (22.4)^[a](#table-fn15-1534735418810799){ref-type="table-fn"}^    338 (23.9)^[a](#table-fn15-1534735418810799){ref-type="table-fn"}^
   Neutropenia         393 (24.6)       43 (23.4)                                                            305 (21.5)^[a](#table-fn15-1534735418810799){ref-type="table-fn"}^
   Thrombocytopenia    235 (14.7)       18 (9.8)                                                             134 (9.4)^[a](#table-fn15-1534735418810799){ref-type="table-fn"}^
  Performance status                                                                                         
   Deterioration       59 (3.7)         4, (2.2)                                                             2 (0.2)^[a](#table-fn15-1534735418810799){ref-type="table-fn"},[b](#table-fn16-1534735418810799){ref-type="table-fn"}^
   Stabilization       1493 (93.3)      167 (91.2)^[a](#table-fn15-1534735418810799){ref-type="table-fn"}^   1290 (91.0)^[a](#table-fn15-1534735418810799){ref-type="table-fn"}^
   Improvement         48 (3.0)         12 (6.6)^[a](#table-fn15-1534735418810799){ref-type="table-fn"}^     125 (8.8)^[a](#table-fn15-1534735418810799){ref-type="table-fn"}^

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; CR, creatinine.

*P* \< .05 compared with non-Aidi group.

*P* \< .05 compared with Aidi group with less than conventional dosage.

Combined Medication Information {#section14-1534735418810799}
-------------------------------

To explore the real clinical combined medication rules of Aidi injection and determine whether there was a difference in medication between the 2 groups, the prescriptions of patients during chemotherapy were collected. The 9 most commonly used kinds of Western medicines and 5 kinds of traditional Chinese medicines are listed in [Table 10](#table10-1534735418810799){ref-type="table"}. Glucocorticoid, antiemetic drugs, painkillers, stomach drugs, antiallergic drugs, and Chinese medicines, which were mainly extracted from ginseng were the most commonly used drugs. Notably, there is no statistical difference between the two groups, which further showed that the difference in QoL between Aidi users and non-Aidi users could be attributed to the Aidi injection. As shown in [Figure 4A](#fig4-1534735418810799){ref-type="fig"} and [B](#fig4-1534735418810799){ref-type="fig"}, the highest frequency (except Aidi injection) of joint use were dexamethasone plus metoclopramide plus tropisetron both in the Aidi group and non-Aidi group (the stronger the link is in the figure, the higher the frequency of combined use).

###### 

Combined Medication Information.

![](10.1177_1534735418810799-table10)

                            Aidi Injection Used                        
  ------------------------- --------------------- ------ ------ ------ ------
  Dexamethasone             1126                  70.3   1112   69.5   .589
  Metoclopramide            1049                  65.5   1037   64.8   .656
  Tropisetron               911                   56.9   905    56.6   .830
  Pantoprazole sodium       706                   44.1   703    43.9   .915
  Omeprazole                231                   14.4   229    14.3   .920
  Clonazepam                179                   11.2   163    10.2   .360
  Cimetidine                159                   9.9    149    9.3    .549
  Diphenhydramine           185                   11.6   191    11.9   .742
  Tramadol                  143                   8.9    139    8.7    .803
  ShenqiFuzheng injection   503                   31.4   497    31.1   .819
  Glycopeptide injection    424                   26.5   433    27.1   .719
  Kushen injection          255                   15.9   268    16.8   .534
  Shenmai injection         123                   7.7    123    7.7    .999
  DiyuShengbai tablet       50                    3.1    65     4.1    .154

![Analysis of association rules of combined drug use of (A) Aidi users and (B) non-Aidi users.](10.1177_1534735418810799-fig4){#fig4-1534735418810799}

Discussion {#section15-1534735418810799}
==========

In past years, clinical research attached increasing importance to QoL, and a large number of studies investigated QoL as an outcome of cancer treatment. Yet due to the restriction of the subjectivity, complexity, and adherence of patients and physicians, it is difficult to assess QoL in real-world treatment.^[@bibr23-1534735418810799]^ Much research had indicated that PS is associated with QoL from different perspectives. As Moningi and Walker^[@bibr25-1534735418810799]^ reported, patients with the worse PS are correlated with worse QoL. It was reported in another study that higher QoL is significantly associated with better PS, and in the lower the QoL, the lower the PS will be.^[@bibr24-1534735418810799]^ Apart from PS, several reports had suggested that QoL and chemotherapy-related toxicity are significantly correlated.^[@bibr28-1534735418810799],[@bibr29-1534735418810799]^ Based on this research, PS served as a major surrogate endpoint in the present study to assess QoL in cancer patients, with the incidence rate of chemotherapy-related toxicity supplied for supplementalevidence. The findings of our study suggested that Aidi injection combined with chemotherapy could decrease the incidence rate of chemotherapy-related toxicity and improve PS in patients as compared with chemotherapy alone, that is, Aidi injection could improve QoL in cancer patients.

In fact, PS refers to a patient's ability to perform activities and functions that meet basic physical needs in the face of illness and is attempt to quantify cancer patient's general well-being and activities of daily life, which are affected by various symptoms and immune functions.^[@bibr28-1534735418810799][@bibr29-1534735418810799]-[@bibr30-1534735418810799]^ Our study has shown that Aidi injection could decrease the incidence rate of various symptoms caused by chemotherapy, including nausea, vomiting, and so on ([Tables 3](#table3-1534735418810799){ref-type="table"} and [4](#table4-1534735418810799){ref-type="table"}). This might be due to the ability of Aidi injection to support body energy, clearing away heat and toxicity. Additionally, immune function damage is a serious toxicity, including lower antitumor and anti-infective immunity induced by chemotherapy, and is a major factor influencing PS. According to several studies, Aidi injection could significantly increase the percentage of CD3+ cells, CD4+ T cells, CD8+ T cells, NK cells, and the CD4+/CD8+ T cells ratio of peripheral blood and reverse the Th1/Th2 shift. These results revealed that Aidi injection could enhance cellular immunity.^[@bibr31-1534735418810799],[@bibr32-1534735418810799]^ In addition, many studies have also shown that ginseng, Astragaloside and Cantharidin have immune regulation functions, which indirectly confirms that Aidi injection might enhance PS through improving immune function.^[@bibr14-1534735418810799][@bibr15-1534735418810799]-[@bibr16-1534735418810799]^

Generally speaking, confounding factors are the major problem inherent in observational studies, which can affect persuasiveness. Addressing these known and unknown confounders was carefully considered in the study design: PSM was conducted to group patients^[@bibr33-1534735418810799]^ and the chemotherapy-related toxicities were then compared after PSM. Damage to liver and renal and gastrointestinal reactions that occurred during chemotherapy in the Aidi group were significantly less than that in the control group, as shown in [Table 3](#table3-1534735418810799){ref-type="table"}. The 2 groups had statistically significant difference in the incidence rate of leukopenia, neutropenia, and thrombocytopenia, particularly leukopenia and thrombocytopenia (*P* \< .001, *P* = .033, and *P* \< .001, respectively). This finding is probably because of Astrgaloside,^[@bibr16-1534735418810799]^ one of the main ingredients of Aidi injection, which can promote the proliferation of bone-marrow stem cells. Apart from PSM, stratification and multivariate modeling were conducted to adjust the impact of confounding factors. The PS benefit of using Aidi injection remained consistent after adjustment for a large number of factors including age, gender, TNM stage, and other variables ([Table 6](#table6-1534735418810799){ref-type="table"}). Regardless of gender, age, TNM stage, node metastasis, prior chemotherapy, baseline ECOG score, chemotherapy regimens, other Chinese medicines as well as different chemotherapy cycles, the PS benefit of Aidi injection was confirmed in the stratified analysis. By adjusting the model, the probability of false results is likely to be low, most interference of confounding factors can be eliminated, and the validity of our results can increase. Besides, this study suggests that patients taking Aidi injection in conventional dosages might experience a higher improvement rate of PS and lower incidence rate of chemotherapy-related toxicity compared to the non-Aidi group and the group receiving lower dosages. The benefit of Aidi injection for patients was further supported by this finding.

Our results showed that patients with gastric cancer had a lower improvement rate of PS in comparison with the patients with lung cancer, breast cancer, cardiac and esophageal cancer, as well as ovarian cancer. This is probably because 70.16% patients with gastric cancer in our study had gastric surgery before enrollment, which might result in various symptoms, including loss of body weight and malnutrition.^[@bibr34-1534735418810799]^ The resulting symptoms could cause significant deterioration in their PS.^[@bibr35-1534735418810799]^ Yet from the subgroup of gastric cancer in the stratified analysis, the improvement rate of PS in the Aidi group was significantly higher than that in the control group (OR = 3.7, 95% CI 1.9-7.2). This suggests that patients with gastric cancer could benefit from Aidi injection, although gastric cancer is a factor associated with worse PS. This benefit might be attributed to inclusion of Ciwujia (*Eleutherococcus senticosus*) among the main ingredients of Aidi injection,^[@bibr8-1534735418810799]^ which has been shown to replenish the vital essence and alleviate poor appetite.^[@bibr36-1534735418810799]^ These results revealed that patients with gastric cancer could benefit from using Aidi injection compared with non-Aidi-users.

Hepatic insufficiency caused by chronic liver disease or liver metastasis, a poor prognostic factor for cancer patients, was found in 518 patients in the study group.^[@bibr37-1534735418810799][@bibr38-1534735418810799][@bibr39-1534735418810799][@bibr40-1534735418810799]-[@bibr41-1534735418810799]^ In our study, the result of presence of hepatic insufficiency substantially inhibited any gains (OR = 0.5, 95% CI 0.2-1.0) in PS compared with normal liver function. Because of the protective effect of Astragaloside on liver injury,^[@bibr16-1534735418810799],[@bibr42-1534735418810799],[@bibr43-1534735418810799]^ Aidi injection reduced the incidence rate of liver injury ([Table 3](#table3-1534735418810799){ref-type="table"}). Still, patients using Aidi injection showed no advantages in the improvement rate of PS in comparison with the patients not using Aidi injection in the hepatic insufficiency subgroup ([Figure 3](#fig3-1534735418810799){ref-type="fig"}). Besides, in the Aidi group, patients with hepatic insufficiency show no significant difference compared with those with normal liver function (OR = 0.5, 95%CI 0.2-1.8, *P* \< .001) ([Table 7](#table7-1534735418810799){ref-type="table"}). Hepatic insufficiency, which affects the detoxification and metabolic functions of the liver, might also alter the effect of Aidi injection. Unfortunately, the specific reasons still need further exploration because of the complex effective components of TCM. Given this problem, we are making preparation to conduct further relevant study on Aidi injection and liver injury, to supplement clinical evidence.

In this study, to explore the information of the combined medication of Aidi injection, the prescriptions of patients receiving chemotherapy were collected ([Table 10](#table10-1534735418810799){ref-type="table"}). By conducting the association rule model,^[@bibr44-1534735418810799]^ we found there was no significant difference in the drug combination between Aidi users and non-Aidi users ([Figure 4A](#fig4-1534735418810799){ref-type="fig"} and [B](#fig4-1534735418810799){ref-type="fig"}). Thus, we further demonstrated that the difference in QoL between the 2 groups was the effect of Aidi injection. Based on this model, thousands of combined medication rules were revealed and it was difficult to compare the impact of these rules of drug use on QoL. In a follow-up study, we will pay more attention to the most effective combination of Aidi injection. Yet our research has shown Aidi injection as the main factor on QoL and demonstrated the clinical effect of the combined medication of Aidi injection, which might be meaningful for clinical rational drug use.

The strengths of the present study consist of the large sample size and the fact that we had collected more detailed information, inclusive of routine blood work, blood biochemistry and combined medication information before and after treatment. Its size and the fact that it was extracted from real-world data provide a robust profile of PS for these patients in conditions of usual clinical practice. The findings of this study suggested a positive causal link between Aidi injection and the QoL of cancer patients receiving chemotherapy. It is reasonably assumed that this integrative approach might be recommended to patients.

Limitations of our study were a result of the retrospective design. First and foremost, the findings were limited by potential and unrecognized confounding factors, for example, drinking and smoking. Yet these are considered unimportant factors determining patients' entry into the cohort groups. Second, our data were collected from EMR database in hospital, where some problems remained. Because of the mobility of patients in large hospitals and limited time of follow-up, the outcome of survival time could not be explored in this study. Third, patients with longer hospitalization days (eg, longer chemotherapy cycle) have a better chance to use Aidi injection. Although we strive to conquer this problem by matching the baseline characteristics and apply logistic regression model to adjust all of the covariates in 2 groups, we cannot overstate the findings. However, to the best of our knowledge, this study is still the largest observational study to investigate the effectiveness of Aidi injection for patients with different types of cancer who receiving chemotherapy on the basis of real-world data, which might provide robust evidence.

Conclusion {#section16-1534735418810799}
==========

This retrospective cohort study showed that Aidi injection as adjuvant to chemotherapy might improve the QoL in cancer patients by improving PS and reducing incident rate of chemotherapy-related toxicity. In addition, because of excellent effect of Aidi injection on patients with different types of cancer, it should be recommended to apply in clinical work.
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